Rotraut Mössner

Dr. Rotraut Mössner


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2014 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
UHU. Hüffmeier
U. Hüffmeier
MWM. Wätzold
M. Wätzold
JMJ. Mohr
J. Mohr
MSM.P. Schön
M.P. Schön
RMRotraut Mössner
Rotraut Mössner

5 August 2017 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
RMRotraut Mössner
Rotraut Mössner
DWD. Wilsmann-Theis
D. Wilsmann-Theis
VOV. Oji
V. Oji
PGP. Gkogkolou
P. Gkogkolou
SLS. Löhr
S. Löhr
UHU. Hüffmeier
U. Hüffmeier
Background Rare variants in the genes IL36RN, CARD14 and AP1S3 have been identified to cause or contribute to pustular skin diseases, primarily generalized pustular psoriasis (GPP). Objectives To better understand the disease relevance of these genes, we screened our cohorts of patients with pustular skin diseases [primarily GPP and palmoplantar pustular psoriasis (PPP)] for coding changes in these three genes. Carriers of single heterozygous IL36RN mutations were screened for a second mutation in IL36RN. Methods Coding exons of IL36RN, CARD14 and AP1S3 were sequenced in 67 patients – 61 with GPP, two with acute generalized exanthematous pustulosis and four with acrodermatitis continua of Hallopeau. We screened IL36RN and AP1S3 for intragenic copy‐number variants and 258 patients with PPP for coding changes in AP1S3. Eleven heterozygous IL36RN mutations carriers were analysed for a second noncoding IL36RN mutation. Genotype–phenotype correlations in carriers/noncarriers of IL36RN mutations were assessed within the GPP cohort. Results The majority of patients (GPP, 64%) did not carry rare variants in any of the three genes. Biallelic and monoallelic IL36RN mutations were identified in 15 and five patients with GPP, respectively. Noncoding rare IL36RN variants were not identified in heterozygous carriers. The only significant genotype–phenotype correlation observed for IL36RN mutation carriers was early age at disease onset. Additional rare CARD14 or AP1S3 variants were identified in 15% of IL36RN mutation carriers. Conclusions The identification of IL36RN mutation carriers harbouring additional rare variants in CARD14 or AP1S3 indicates a more complex mode of inheritance of pustular psoriasis. Our results suggest that, in heterozygous IL36RN mutation carriers, there are additional disease‐causing genetic factors outside IL36RN.

1 July 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SFSilke Frey
Silke Frey
HSHeinrich Sticht
Heinrich Sticht
DWDagmar Wilsmann-Theis
Dagmar Wilsmann-Theis
AGAnne Gerschütz
Anne Gerschütz
KWKatharina Wolf
Katharina Wolf
UHUlrike Hüffmeier
Ulrike Hüffmeier

26 January 2021 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
CKChristian Kromer
Christian Kromer
ELEmilia Loewe
Emilia Loewe
MSMarthe‐Lisa Schaarschmidt
Marthe‐Lisa Schaarschmidt
APAndreas Pinter
Andreas Pinter
SGSascha Gerdes
Sascha Gerdes
DWDagmar Wilsmann‐Theis
Dagmar Wilsmann‐Theis
Generalized pustular psoriasis (GPP) is a rare, potentially life‐threatening inflammatory skin disease. Our aim was to assess patient and disease characteristics and analyze drug survival rates in the treatment of GPP in a real‐life setting. In this retrospective study, 201 treatment series of 86 patients with GPP treated at five University Medical Centers were analyzed. Overall, excellent response was reached in 41.3% of all treatment courses, partial response in 31.4%, and nonresponse in 27.3%. Biological treatment was significantly more effective than non‐biological therapies (excellent response: 47.4% vs 35.9%; P = .02). Overall, the median drug survival was 14.0 months (biologicals: 36.0 months vs nonbiologicals: 6.0 months; P < .001). The crude probability of survival was highest for secukinumab (hazard ratio [HR] of drug discontinuation compared with acitretin: 0.22), followed by ixekizumab and ustekinumab (HR: 0.38 each), adalimumab (HR: 0.59), etanercept (HR: 0.62), infliximab (HR: 0.69), cyclosporine (HR: 1.00), acitretin (reference for HR), fumaric acid esters (HR: 1.06), methotrexate (HR: 1.26), and apremilast (HR: 3.44); no drug discontinuation with guselkumab. Our results reveal high efficacy and drug survival, particularly for IL‐17 and IL‐(12)/23 antagonists. Thus, these biologics may be considered early in the therapeutic algorithm of GPP.

6 March 2015 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
RMRotraut Mössner
Rotraut Mössner
LZL Zimmer
L Zimmer
CBC Berking
C Berking
CHC Hoeller
C Hoeller
CLC Loquai
C Loquai
SUS Ugurel
S Ugurel

11 November 2021 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
PDF file
NKNeda Rahbar Kooybaran
Neda Rahbar Kooybaran
GPGolo Petzold
Golo Petzold
PSPhilipp Ströbel
Philipp Ströbel
MSMichael P. Schön
Michael P. Schön
RMRotraut Mössner
Rotraut Mössner
Click on the article title to read more.